[en] Statins are essential drugs for the prevention of coronary and cerebral vascular complications. Besides their specific cholesterol-lowering effect, these agents exert various pleiotropic effects, which probably contribute to the cardiovascular protection, but may also play a favourable effect in various other pathologies. Some recent data suggested that statins may play a positive effect in the prevention of Alzheimer disease and colorectal cancer. In contrast, after some initial hope, recent observations in the field of osteoporosis prevention provided discordant and finally rather disappointing results. New prospective studies are mandatory before accepting such new potential indications of statins.
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Sadzot, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Neurologie Sart Tilman
Language :
French
Title :
Quelles indications pour les statines hormis le traitement de l'hypercholesterolemie?
Alternative titles :
[en] Which indications for statins besides their cholesterol-lowering effect?
Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. BMJ 2003;326:1423-7.
Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J 2003;24:225-48.
Mason JC. Statins and their role in vascular protection. Clin Sci 2003;105:251-66.
Waldman A, Kritharides L. The pleiotropic effects of HMG-CoA reductase inhibitors. Their role in osteoporosis and dementia. Drugs 2003;63:139-52.
Sadzot B, Hans G, Bottin P, Moonen G. Des satines pour le cerveau? Rev Med Liège 2003;58:621-7.
Sparks DL, Martin TA, Gross DR, et al. Link between heart disease, cholesterol, and Alzheimer's disease: A review. Micros Res Tech 2000;50:287-90.
Simons M, Keller P, Dichgans J, et al. Cholesterol and Alzheimer's disease: Is there a link? Neurology 2001;57:1089-93.
Fassbender K, Stroick M, Bertsch T, et al. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 2002;59:1257-8.
Wolozin B, Kellman W, Rousseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-43.
Jick H, Zornberg GL, Jick S, et al. Statins and the risk of dementia. Lancet 2000;356:1627-31.
Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002;360:1623-30.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals. Lancet 2002;360:7-22.
Sparks DL, Connor D, Lopez J, et al. Benefit of atorvastatin in the treatment of Alzheimer disease (abstract). Neurobiol Aging 2004;25:524.
Pfeilschifter J, Koditz R, Pfohl M, et al. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 2002;23:90-119.
Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946-9.
Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women (Research Letter). Lancet 2000;355:2218-9.
Sirola J, Honkanen R, Kroger H, et al. Relation of statin use and bone loss: A prospective population-based cohort study in early postmenopausal women. Osteoporos Int 2002;13:537-41.
LaCroix AZ, Cauley JA, Pettinger M, et al. Statin use, clinical fracture, and bone density in postmenopausal women: Results from the Women's Health Initiative Observational Study. Ann Intern Med 2003;139:97-104.
Rejnmark L, Buus NH, Vestergaard P, et al. Effects of simvastatin on bone turnover and BMD: A 1-year randomized controlled trial in postmenopausal osteopenic women. J Bone Miner Res 2004;19:737-44.
Meier CR, Schlienger RG, Kraenzlin ME, et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;283:3205-10.
Pasco JA, Kotowicz MA, Henry MJ, et al. Statin use, bone mineral density, and fracture risk. Geelong Osteoporosis Study. Arch Intern Med 2002;162:537-40.
van Staa T-P, Wegman S, de Vries F, et al. Use of statins and risk of fractures. JAMA 2001;285:1850-5.
McClung M, Kiel D, Lindsay R, et al. A 12-month, dose-response study of atorvastatin effects on bone in postmenopausal women. Poster presented at the American Society of Bone and Mineral Research Annual Meeting 2004, October, 3, 2004, Seattle, WA, USA.
Buchwald H. Cholesterol inhibition, cancer, and chemotherapy. Lancet 1992;339:1154-6.
Poytnter JN, Gruber SB, Higgins PDR, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005;352:2184-92.
Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: A nested case-control study. Arch Intern Med 2000;160:2363-8.
Graaf MR, Beiderbeck AB, Egberts AC, et al. The risk of cancer in users of statins. J Clin Oncol 2004;22:2388-94.
Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004;90:635-7.
